Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Subject characteristics

From: Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

Group: E A B C D
Characteristic Placebo N = 60 60 μg + Al N = 40 60 μg N = 40 90 μg + Al N = 40 90 μg N = 40
Gender, n (%)
 Male 22 (37) 18 (45) 16 (40) 21 (53) 17 (43)
 Female 38 (63) 22 (55) 24 (60) 19 (48) 23 (58)
Race, n (%)
 White or Caucasian 58 (97) 40 (100) 39 (98) 37 (93) 40 (100)
 Black or African American 1 (2) 0 0 3 (8) 0
 Asian 0 0 0 0 0
 American Indian/Alaska Native 0 0 0 0 0
 Native Hawaiian/Other Pacific Islander 0 0 0 0 0
 Other 1 (2) 0 1 (3) 0 0
Ethnicity, n (%)
 Hispanic or Latino 0 0 1 (3) 2 (5) 3 (8)
 Not Hispanic or Latino 60 (100) 40 (100) 39 (98) 38 (95) 37 (93)
Age Group (years), n (%)
 60 to < 75 51 (85) 34 (85) 34 (85) 34 (85) 34 (85)
  ≥ 75 9 (15) 6 (15) 6 (15) 6 (15) 6 (15)
Age (years)
 n 60 40 40 40 40
 Mean (SD) 69.1 (5.5) 69.1 (5.8) 67.7 (5.6) 68.0 (5.8) 68.7 (5.7)
 Median 68.0 68.0 67.0 68.0 68.0
 Min, Max 60, 87 60, 83 60, 85 60, 85 61, 81
  1. Percentages are based on the number of subjects in the Safety Population with non-missing data within treatment group
  2. Age is calculated as the closest integer result of (Date of Study day 0 – Date of Birth)/365.25